Deal Snapshot
IMUGENE ACQUIRES ONCOLYTIC VIRUS FROM CANCER CENTRE CITY OF HOPE
Wednesday 17 July 2019

Australian immuno-oncology company Imugene Ltd (ASX: IMU) will acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive licence to a promising oncolytic virus technology, known as CF33, developed at US-based research and treatment centre City of Hope, the company said.
CF33 is a chimeric vaccinia poxvirus from the lab of Professor Yuman Fong, chair of Surgery at city of Hope, and a noted expert in the oncolytic virus field. Oncolytic viruses are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 17/07/2019
Target: Worldwide exclusive licence to CF33
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Financing: Cash and Stock
Status: Agreed
Vendor:
Buyer: Hitachi Data Systems Corp
Comment:
Terms of the deal were not disclosed

Options